Surgery
Volume 146, Issue 6 , Pages 1215-1223 , December 2009

Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation

  • Linwah Yip, MD

      Affiliations

    • Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • Corresponding Author InformationReprint requests: Linwah Yip, MD, Kaufmann Building, Suite 101, 3471 Fifth Avenue, Pittsburgh, PA 15213.
    • ,
  • Marina N. Nikiforova, MD

      Affiliations

    • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • Sally E. Carty, MD

      Affiliations

    • Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • John H. Yim, MD

      Affiliations

    • Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • Michael T. Stang, MD

      Affiliations

    • Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • Mitchell J. Tublin, MD

      Affiliations

    • Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • Shane O. LeBeau, MD

      Affiliations

    • Department of Endocrinology, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • Steven P. Hodak, MD

      Affiliations

    • Department of Endocrinology, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • Jennifer B. Ogilvie, MD

      Affiliations

    • Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • Yuri E. Nikiforov, MD

      Affiliations

    • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA

,Accepted 17 September 2009.

References 

  1. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22:901–911
  2. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175–5180
  3. Rowe LR, Bentz BG, Bentz JS. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal. 2006;10:3–10
  4. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092–2098
  5. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAFV600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007;110:38–46
  6. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–5404
  7. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085–4090
  8. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466–471
  9. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–6379
  10. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol. 2006;65:364–368
  11. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol. 2007;68:618–634
  12. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, et al. BRAF V600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943–3949
  13. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454–1457
  14. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 1998;83:2638-2648.
  15. Lefevre JH, Tresallet C, Leenhardt L, Jublanc C, Chigot JP, Menegaux F. Reoperative surgery for thyroid disease. Langenbecks Arch Surg. 2007;392:685–691
  16. Kim MK, Mandel SH, Baloch Z, Livolsi VA, Langer JE, Didonato L, et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolarngol Head Neck Surg. 2004;130:1214–1216
  17. Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid. 2008;18:1179–1181
  18. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216–222
  19. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946–955
  20. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238–4245
  21. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, et al. BRAF V600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer. 2008;15:511–520
  22. Lie D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 2007;13:41–49

PII: S0039-6060(09)00540-6

doi: 10.1016/j.surg.2009.09.011

Surgery
Volume 146, Issue 6 , Pages 1215-1223 , December 2009

Article Tools

* Image Usage & Resolution